arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

BIOMERICA INC

BMRA
$2.63 ▼ -0.10 (-3.66%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
17 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOMERICA INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.7M
Dividend Yield
Revenue Growth -16.2%
Op. Margin -119.5%
ROIC -203.5%
FCF / Share $-1.17
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.45M
↓ -16.2%
Net Income Profit after all expenses
$-3.77M
↑ +24.1%
Operating Margin Operating profit as % of sales
-119.5%
↓ -23.5% 0th
FCF / Share Free cash flow per share
$-1.17
↑ +29.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
4
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 64 quarters